Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date
“We are exceptionally proud to continue supporting our community with SARS-CoV-2 testing and providing healthcare providers with rapid turnaround of valuable information to help contain viral spread,” said
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding our ability to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005224/en/
Investor Contact:
LHA Investor Relations
Jcain@lhai.com, (310) 691-7100
Media Contact:
asampson@sampsonprgroup.com, (562) 304-0301
Source: